| Literature DB >> 34487190 |
Lillian J Brady1,2, Kirsty R Erickson1,2,3, Drew D Kiraly4,5,6,7, Erin S Calipari8,9,10,11,12,13, Kelsey E Lucerne14,15, Aya Osman14,15,16,17.
Abstract
Cocaine use disorder is associated with alterations in immune function including altered expression of multiple peripheral cytokines in humans-several of which correlate with drug use. Individuals suffering from cocaine use disorder show altered immune system responses to drug-associated cues, highlighting the interaction between the brain and immune system as a critical factor in the development and expression of cocaine use disorder. We have previously demonstrated in animal models that cocaine use upregulates the expression of granulocyte colony-stimulating factor (G-CSF)-a pleiotropic cytokine-in the serum and the nucleus accumbens (NAc). G-CSF signaling has been causally linked to behavioral responses to cocaine across multiple behavioral domains. The goal of this study was to define whether increases in G-CSF alter the pharmacodynamic effects of cocaine on the dopamine system and whether this occurs via direct mechanisms within local NAc microcircuits. We find that systemic G-CSF injection increases cocaine effects on dopamine terminals. The enhanced dopamine levels in the presence of cocaine occur through a release-based mechanism, rather than through effects on the dopamine transporter-as uptake rates were unchanged following G-CSF treatment. Critically, this effect could be recapitulated by acute bath application of G-CSF to dopamine terminals, an effect that was occluded by prior G-CSF treatment, suggesting a similar mechanistic basis for direct and systemic exposures. This work highlights the critical interaction between the immune system and psychostimulant effects that can alter drug responses and may play a role in vulnerability to cocaine use disorder.Entities:
Keywords: Cocaine; Granulocyte colony-stimulating factor; Nucleus accumbens
Mesh:
Substances:
Year: 2021 PMID: 34487190 PMCID: PMC9056006 DOI: 10.1007/s00213-021-05967-9
Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN: 0033-3158 Impact factor: 4.415